Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Acute kidney injury frequently affects cancer patients. The main cause of acute kidney injury
is ischemic damage caused by transient decrease in renal blood flow, followed by blood flow
restoration and accompanying reperfusion injury (ischemia-reperfusion injury. Several
studies, mainly in animal models have tried to establish spironolactone role on kidney injury
induced by ischemia-reperfusion injury. It has been demonstrated in renal transplant
recipients that the administration of spironolactone can prevent oxidative stress and is
safe. The group of cancer patients with states capable of producing tissue hypoperfusion
(hypovolemic shock, heart failure, major surgery, use of anesthetics) are at increased risk
of developing acute renal ischemia-reperfusion injury.
The investigators hypothesis is that spironolactone may be useful in preventing acute renal
injury when administered during the first six hour of renal ischemia-reperfusion insult.
The purpose of this study is to determine the utility of spironolactone administered after an
ischemic renal insult (major surgery) to prevent acute kidney injury in critically cancer
patients.
Investigators propose a pilot study, randomized, double blind, placebo controlled trial,
approved by the local ethical committee, to compare the efficacy of spironolactone to prevent
acute kidney injury in patients after major surgery. Investigators will include 12 patients
in spironolactone group (25mg daily for three days) and 12 patients in placebo group.